Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Plos Pathogens|October 3, 2012
Relacin, a novel antibacterial agent targeting the Stringent ResponseEzequiel Wexselblatt, Yaara Oppenheimer-Shaanan, Ilana Kaspy, et al.Proceedings of the National Academy of Sciences of the United States of America|March 2, 2005
Protein-DNA charge transport: redox activation of a DNA repair protein by guanine radicalEylon Yavin, Amie K Boal, Eric D A Stemp, et al.Plos One|November 13, 2012
Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factorGadi Cohen, Shimon Lecht, Hadar Arien-Zakay, et al.Cancer Letters|February 19, 2013
Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beaconsYossi Kam, Abraham Rubinstein, Shankar Naik, et al.International Journal of Cancer|April 25, 2019
MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcomaVadim V Maximov, Rania Akkawi, Saleh Khawaled, et al.Pharmaceutics|September 28, 2024
Differential Effect of Simulated Microgravity on the Cellular Uptake of Small MoleculesOdelia Tepper-Shimshon, Nino Tetro, Roa'a Hamed, et al.Journal of Cell Science|May 21, 2013
PfSec13 is an unusual chromatin-associated nucleoporin of Plasmodium falciparum that is essential for parasite proliferation in human erythrocytesNoa Dahan-Pasternak, Abed Nasereddin, Netanel Kolevzon, et al.Nature Communications|April 10, 2019
Specific inhibition of splicing factor activity by decoy RNA oligonucleotidesPolina Denichenko, Maxim Mogilevsky, Antoine Cléry, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 2, 2018
Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastomaGalia Tiram, Shiran Ferber, Paula Ofek, et al.Proceedings of the National Academy of Sciences of the United States of America|December 4, 2013
Mutant KRAS is a druggable target for pancreatic cancerElina Zorde Khvalevsky, Racheli Gabai, Itzhak Haim Rachmut, et al.Pageof 6